USP22 and lung carcinoma: We found that the USP7-specific inhibitor FT671 [12] dramatically upregulates USP22 protein in a dose-dependent manner, even at a very low concentration that barely affects cellular proliferation in lung cancer cell line A549 (Fig. 1A).